Personalized medicine for lung cancer: New challenges for pathology

Histopathology

Volumn 60, Issue 4, 2012, Pages 531-546

  Kerr, Keith M ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Biomarkers; Diagnosis; Dihydrofolate reductase; EML4 ALK; Epidermal growth factor receptor; Immunohistochemistry; Kirsten rat sarcoma; Non small cell lung cancer; P63; Pathology; Personalized therapy; Targeted therapy; Thymidilate synthase; Thyroid transcription factor 1

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; B RAF KINASE; BEVACIZUMAB; BIOLOGICAL MARKER; CARBOPLATIN; CARCINOEMBRYONIC ANTIGEN; CD135 ANTIGEN; CETUXIMAB; CISPLATIN; CYTOKERATIN 14; CYTOKERATIN 5; CYTOKERATIN 6; CYTOKERATIN 7; DESMOCOLLIN; DIHYDROFOLATE REDUCTASE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; PEMETREXED; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; PROTEIN P63; PSORIASIN; SOMATOMEDIN RECEPTOR; SORAFENIB; THYMIDYLATE SYNTHASE; THYROID TRANSCRIPTION FACTOR 1; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER SURVIVAL; CELL DIVISION; CYTOLOGY; CYTOTOXICITY; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DNA EXTRACTION; DNA SYNTHESIS; DRUG EFFICACY; DRUG SAFETY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DOSAGE; GENE MUTATION; GENE SEQUENCE; GENETIC CODE; HEMOPTYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH RESOLUTION MELTING ANALYSIS; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; LASER CAPTURE MICRODISSECTION; LIMIT OF DETECTION; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MEASUREMENT; MOLECULARLY TARGETED THERAPY; MORPHOLOGY; ONCOGENE C KIT; PATHOLOGIST; PERSONALIZED MEDICINE; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PYROSEQUENCING; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVIEW; SINGLE STRAND CONFORMATION POLYMORPHISM; SMALL CELL CARCINOMA; TUMOR BIOPSY; TUMOR NECROSIS;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS;

RATTUS;

EID: 84857043356     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.03854.x     Document Type: Review

References (112)

1. Assaraf YG. Molecular basis of antifolate resistance. Cancer Metastasis Rev. 2007; 26; 153-181.
2. Ceppi P, Volante M, Saviozzi S et al. Squamous cell carcinoma of the lung compared to other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 2006; 107; 1589-1596.
3. Socinski MA, Smit EF, Lorigan P et al. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer. J. Clin. Oncol. 2009; 27; 4787-4792.
4. Scagliotti GV, Parikh P, Pawel JV et al. Phase III study comparing Cisplatin plus Gemcitabine with Cisplatin plus Pemetrexed in chemotherapy-naïve patients with advanced-stage Non-small cell lung cancer. J. Clin. Oncol. 2008; 26; 1-10.
5. Hanna N, Shepherd FA, Fossella FV et al. Randomised pahse III trail of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J. Clin. Oncol. 2004; 22; 1589-1597.
6. Scagliotti G, Hanna N, Fossella F et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 2009; 14; 253-263.
7. Ciuleanu T, Brodowicz T, Zielinski C et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009; 374; 1432-1440.
8. Ardizzoni A, Boni L, Tiseo M et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J. Natl Cancer Inst. 2007; 99; 847-857.
9. Hirsch FR, Spreafico A, Novello S et al. The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review. J. Thorac. Oncol. 2008; 3; 1468-1481.
10. Johnson DH, Fehrenbacher L, Novotny WF et al. Randomized phase II trail comparing bevacizumab plus carboplatin and paclitaxel with carboplatinand paclitaxel alone in previously untreated locally advanced ormetastatic non-small cell lung cancer. J. Clin. Oncol. 2004; 22; 2184-2191.
11. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N. Engl. J. Med. 2006; 355; 2542-2550.
12. Scagliotti GV, Novello S, von Pawel J et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small cell lung cancer. J. Clin. Oncol. 2010; 28; 1835-1842.
13. Riely GJ, Politi KA, Miller VA et al. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin. Cancer Res. 2006; 12; 7232-7241.
14. Misudomi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci. 2007; 98; 1817-1824.
15. Rosell R, Moran T, Queralt C et al. Screening for epidermal growth factor receptor mutations in lung cancer. N. Engl. J. Med. 2009; 361; 958-967.
16. Marchetti A, Martella C, Felicioni L et al. EGFR mutations in non-small cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J. Clin. Oncol. 2005; 23; 857-865.
17. Tsao AS, Tang XM, Sabloff B et al. Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer. J. Thorac. Oncol. 2006; 1; 231-239.
18. Sartori G, Cavazza A, Sgambato A et al. EGFR and KRAS mutations along the spectrum of pulmonary epithelial tumours of the lung and elaboration of a combined clinicopathologic and molecular scoring system to predict clinical responsiveness to EGFR inhibitors. Am. J. Clin. Pathol. 2009; 131; 478-489.
19. Dziadziuszko R, Camidge DR, Hirsch FR. The insulin-like growth factor pathway in lung cancer. J. Thorac. Oncol. 2008; 3; 815-818.
20. Travis WD, Brambilla E, Muller-Hermelink HK et al. eds. World Health Organisation Classification of tumours. Pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon: IARC Press, 2004.
21. Schreiber G, McCrory DC. Performance characteristics of different modalities for diagnosis of suspected lung cancer: summary of published evidence. Chest 2003; 123; 115-128.
22. Rivera MP, Detterbeck F, Mehta AC. Diagnosis of lung cancer: the guidelines. Chest 2003; 123; 129-136.
23. Lyall MS, Chapman AD, Kerr KM. The diagnosis of lung cancer on bronchoscopic biopsy. CPD Bull. Cell Path. 2006; 6; 20-30.
24. Kerr KM, Kwon KY, Ro JY. Neuroendocrine tumours. In Cagle PT, Allen TC, Kerr KM eds. Transbronchial and endobronchial biopsies. Philadelphia: Lippincott Williams & Wilkins, 2009; 21-28.
25. Burnett RA, Swanson Beck J, Howatson SR et al. Observer variability in histopathological reporting of malignant bronchial biopsy specimens. J. Clin. Pathol. 1994; 47; 711-713.
26. Field RW, Smith BJ, Platz CE et al. Lung cancer histologic type in the surveillance, epidemiology and end results registry versus independent review. J. Natl Cancer Inst. 2004; 96; 1105-1107.
27. Burnett RA, Howatson SR, Lang S et al. Observer variability in histopathological reporting of non-small cell carcinoma on bronchial biopsy specimens. J. Clin. Pathol. 1996; 49; 130-133.
28. Stang A, Pohlabeln H, Müller KM et al. Diagnostic agreement in the histopathological evaluation of lung cancer tissue in a population-based case-control study. Lung Cancer 2006; 52; 29-36.
29. Grilley-Olson JE, Hayes DN, Qaqish BF et al. Diagnostic reproducibility of squamous cell carcinoma in the era of histology-directed non-small cell lung cancer chemotherapy: a large prospective study. J. Clin. Oncol. 2009; 27 (S15); 409.
30. Cataluña JJ, Perpiñá M, Greses JV et al. Cell type accuracy of bronchial biopsy specimens in primary lung cancer. Chest 1996; 109; 1199-1203.
31. Matsuda M, Horai T, Nakamura S et al. Bronchial brushing and bronchial biopsy: comparison of diagnostic accuracy and cell typing reliability in lung cancer. Thorax 1986; 41; 475-478.
32. Chuang MT, Marchevsky A, Teirstein AS et al. Diagnosis of lung cancer by fibreoptic bronchoscopy: problems in the histological classification of non-small cell carcinomas. Thorax 1984; 39; 175-178.
33. Thomas JS, Lamb D, Ashcroft T et al. How reliable is the diagnosis of lung cancer using small biopsy specimens? Report of a UKCCCR Lung Cancer Working Party Thorax 1993; 48; 1135-1139.
34. Edwards SL, Roberts C, McKean ME et al. Preoperative histological classification of primary lung cancer: accuracy of diagnosis and use of the non-small cell category. J. Clin. Pathol. 2000; 53; 537-540.
35. Ou SI, Zell JA. Carcinoma NOS is a common histologic diagnosis and is increasing in proportion among non-small cell lung cancer histologies. J. Thorac. Oncol. 2009; 4; 1202-1211.
36. Coghlin CL, Smith LJ, Bakar S et al. Quantitative analysis of tumor in bronchial biopsy specimens. J. Thorac. Oncol. 2010; 5; 448-452.
37. Loo PS, Thomas SC, Nicolson MC, Fyfe MN, Kerr KM. Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens. J. Thorac. Oncol. 2010; 5; 442-447.
38. Kaufmann O, Fietze E, Mengs J et al. Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. Am. J. Clin. Pathol. 2001; 116; 823-830.
39. Wu M, Wang B, Gil J et al. p63 and TTF-1 immunostaining. A useful marker panel for distinguishing small cell carcinoma of lung from poorly differentiated squamous cell carcinoma of lung. Am. J. Clin. Pathol. 2003; 119; 696-702.
40. Au NHC, Gown AM, Cheang M et al. p63 expression in lung carcinoma. A tissue microarray study of 408 cases. Appl. Immunohistochem. Mol. Morphol. 2004; 12; 240-247.
41. Shtilbans V, Szporn AH, Wu M et al. P63 immunostaining in destained bronchoscopic cytological specimens. Diagn. Cytopathol. 2005; 32; 198-203.
42. Wu M, Szporn AH, Zhang D et al. Cytology applications of p63 and TTF-1 immunostaining in differential diagnosis of lung cancers. Diagn. Cytopathol. 2005; 33; 223-227.
43. Zhang H, Liu J, Cagle PT et al. Distinction of pulmonary small cell carcinoma from poorly differentiated squamous cell carcinoma: an immunohistochemical approach. Mod. Pathol. 2005; 18; 111-118.
44. Camilo R, Capelozzi Vl, Siqueira SA et al. Expression of p63, keratin 5/6 and surfactant-A in non-small cell lung carcinomas. Hum. Pathol. 2006; 37; 542-546.
45. Kargi A, Gurel D, Tuna B. The diagnostic value of TTF-1, CK5/6 and p63 immunostaining in classification of lung carcinomas. Appl. Immunohistochem. Mol. Morphol. 2007; 15; 415-420.
46. Khayyata S, Yun S, Pasha T et al. Value of p63 and CK5/6 in distinguishing squamous cell carcinoma from adenocarcinoma in lung fine-needle aspiration specimens. Diagn. Cytopathol. 2009; 37; 178-183.
47. Rossi G, Marchioni A, Milani M et al. TTF-1, cytokeratin 7, 34βE12 and CD56/NCAM immunostaining in the subclassification of large cell carcinomas of the lung. Am. J. Clin. Pathol. 2004; 122; 884-893.
48. Monica V, Ceppi P, Righi L et al. Desmocollin-3: a new marker of squamous differentiation in undifferentiated large-cell carcinoma of the lung. Mod. Pathol. 2009; 22; 709-717.
49. Conde E, Angulo B, Redondo P et al. The use of p63 immunohistochemistry for the identification of squamous cell carcinoma of the lung. PLoS ONE 2010; 5; e12209.
50. Pelosi G, Pasini F, Olsen Stenholm C et al. P63 immunoreactivity in lung cancer: yet another player in the development of squamous cell carcinomas? J. Pathol. 2002; 198; 100-109.
51. Ring BZ, Seitz RS, Beck RA et al. A novel five-antibody immunohistochemical test for subclassification of lung carcinoma. Mod. Pathol. 2009; 22; 384-396.
52. Sun Z, Yang P. Gene expression profiling on lung cancer outcome prediction: present clinical value and future premise. Cancer Epidemiol. Biomarkers Prev. 2006; 15; 2063-2068.
53. Lebanony D, Benjamin H, Gilad S et al. Diagnostic assay based on has-miR-205 expression distinguishes squamous from non-squamous non-small cell lung carcinoma. J. Clin. Oncol. 2009; 27; 2030-2037.
54. Bishop JA, Benjamin H, Cholakh H et al. Accurate classification of non-small cell lung carcinoma using a novel microRNA-based approach. Clin. Cancer Res. 2010; 16; 610-619.
55. Lim EH, Zhang S-L, Yu K et al. An alternative approach to determining therapeutic choices in advanced non-small cell lung carcinoma (NSCLC): maximising the diagnostic procedure and the use of low volume lung biopsies. J. Thorac. Oncol. 2007; 2; 387-396.
56. Tsao M-S. Should mutational analysis of tumour samples bypass histopathology? J. Thorac. Oncol. 2007; 2; 375-376.
57. National Health Service (NHS) National Institute for Health and Clinical Excellence (NICE). Technology appraisal guidance 192. Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer. London: National Institute for Health and Clinical Excellence, 2010.
58. Gazdar AF. Personalized medicine and inhibition of EGFR signaling in lung cancer. N. Engl. J. Med. 2009; 361; 1018-1020.
59. Paez JG, Janne PA, Lee JC et al. EGRF mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304; 1497-1500.
60. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N. Engl. J. Med. 2004; 350; 2129-2139.
61. Bean J, Brennan C, Shih J-Y et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumours with acquired resistance to gefitinib or erlotinib. Proc. Natl. Acad. Sci. 2007; 104; 20932-20937.
62. Suda K, Onozato R, Yatabe Y et al. EGFR T790M mutation. A double role in lung cancer survival? J. Thorac. Oncol. 2009; 4; 1-4.
63. Cappuzzo F. EGFR FISH versus mutation: different tests, different end-points. Lung Cancer 2008; 60; 160-165.
64. Pham D, Kris MG, Riely GJ et al. Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. J. Clin. Oncol. 2006; 24; 1700-1704.
65. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or Carboplatin-Paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 2009; 361; 947-957.
66. Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or chemotherapy for non-small cell lung cancer with mutated EGFR. N. Engl. J. Med. 2010; 362; 2380-2388.
67. Mitsudomi T, Morita S, Yatabe Y et al. Gefitinib versus cisplatin plus dicetaxel in patients with non small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomized phase 3 trial. Lancet Oncol. 2010; 11; 121-128.
68. Pirker R, Herth FJF, Kerr KM et al. Consensus for EGFR mutation testing in non-small cell lung cancer. Results from a European workshop. J. Thorac. Oncol. 2010; 5; 1706-1713.
69. Pao W, Ladanyi M. Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method. Clin. Cancer Res. 2007; 13; 4974-4983.
70. Murray S, Dahabreh IJ, Linardou H et al. Somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in non-small cell lung cancer: an analytical database. J. Thorac. Oncol. 2008; 3; 832-839.
71. Rosell R, Molina MA, Costa C et al. Outcome to erlotinib in non-small cell lung cancer (NSCLC) patients (p) according to the presence of the EGFR T790M mutation and BRCA1 mRNA expression levels in pretreatment biopsies. Abstract 7514. J. Clin. Oncol. 2010; 28; 542s.
72. Turke AB, Zejnullahu K, Wu Y-L et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010; 17; 77-88.
73. Ding L, Getz G, Wheeler DA. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008; 455; 1069-1075.
74. Massarelli E, Varella-Garcia M, Tang X et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin. Cancer Res. 2007; 13; 2890-2896.
75. Kim ES, Hirsh V, Mok T et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomized phase III trial. Lancet 2008; 372; 1809-1818.
76. Yap TA, Vidal L, Adam J et al. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J. Clin. Oncol. 2010; 28; 3965-3972.
77. Shaw AT, Yeap BY, Mino-Kinudson M et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J. Clin. Oncol. 2009; 27; 4247-4253.
78. Mano H. Non-solid oncogenes in solid tumours. EML4-ALK fusion genes in lung cancer. Cancer Sci. 2008; 99; 2349-2355.
79. Takeuchi K, Choi YL, Soda M et al. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin. Cancer Res. 2008; 14; 6618-6624.
80. Takeuchi K, Choi YL, Togashi Y et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin. Cancer Res. 2009; 15; 3143-3149.
81. Pirker R, Pereira JR, Szczesna A et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009; 373; 1525-1531.
82. Azzoli CG, Park BJ, Pao W et al. Molecularly tailored adjuvant chemotherapy for resected non-small cell lung cancer. A time for excitement and equipoise. J. Thorac. Oncol. 2008; 3; 84-93.
83. Rosell R, Cuello M, Cecere F et al. Treatment of non-small-cell lung cancer and pharmacogenomics: where we are and where we are going. Curr. Opin. Oncol. 2006; 18; 135-143.
84. Olaussen KA, Dunant A, Fouret P et al. DNA repair by ERCC1 in non-small cell lung cancer and cisplatin-based adjuvant chemotherapy. N. Engl. J. Med. 2006; 355; 983-991.
85. Filipits M, Pirker R, Dunant A et al. Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program. J. Clin. Oncol. 2007; 25; 2735-2740.
86. Rosell R, Skrzypski M, Jessem E et al. BRCA1: a novel prognostic factor in resected non-small cell lung cancer. PLoS ONE 2007; 11; e1129.
87. Rosell R, Perez-Roca L, Sanchez JJ et al. Customized treatment in non-small cell lung cancer based on EGFR mutations and BRCA1 mRNA expression. PLoS ONE 2009; 4; e5133.
88. Petty RD, Kerr KM, Murray GI et al. Tumor transcriptome reveals the predictive and prognostic impact of lysosomal protease inhibitors in non-small-cell lung cancer. J. Clin. Oncol. 2006; 24; 1729-1744.
89. Rosell R, Moran T, Viteri S et al. Optimization of genetics to create therapies for metastatic (stage IV) non-small cell lung cancer. Expert Opin. Pharmacother. 2010; 11; 1683-1693.
90. Sève P, Lai R, Ding K et al. Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10. Clin. Cancer Res. 2007; 13; 994-999.
91. Bepler G, Sommers KE, Cantor A et al. Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer. J. Thorac. Oncol. 2008; 3; 1112-1118.
92. Paez-Ares LG, Altug S, Thareau Vaury A et al. Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advanced non-squamous non-small cell lung cancer. BMC Cancer 2010; 10; 85.
93. Kerr KM, Fennell DA, Shah RN et al. Thymidylate synthetase immunohistochemistry: feasibility in a routine clinical setting for patients receiving treatment with pemetrexed for advanced nonsquamous NSCLC. Abstract TPS293. J. Clin. Oncol. 2010; 28; 54s.
94. Reynolds C, Obasaju C, Schell MJ et al. Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small cell lung cancer. J. Clin. Oncol. 2009; 27; 5808-5815.
95. Tyagi P, Mirakhur B. MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy. Clin. Lung Cancer 2009; 10; 371-374.
96. Tomaszek SC, Huebner M, Wigle DA et al. Prospects for molecular staging of non-small cell carcinoma from genomic alterations. Expert Rev. Respir. Med. 2010; 4; 499-508.
97. Custodio AB, Gonzalez-Larriba JL, Bobokova K et al. Prognostic and predictive markers of benefit from adjuvant chemotherapy in early-stage non-small cell lung cancer. J. Thorac. Oncol. 2009; 4; 891-910.
98. Carbone DP, Salmon JS, Billheimer D et al. Veristrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab. Lung Cancer 2010; 69; 337-340.
99. Zhu C-Q, Shih W, Ling C-H et al. Immunohistochemical markers of prognosis on non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation. J. Clin. Pathol. 2006; 59; 790-800.
100. Coate LE, John T, Tsao M-S et al. Molecular predictive and prognostic markers in non-small cell lung cancer. Lancet Oncol. 2009; 10; 1001-1010.
101. Eberhard DA, Giaccone G, Johnson BE. Biomarkers of response to epidermal growth factor receptor inhibitors in non-small cell lung cancer working group: standardization for use in the clinical trial setting. J. Clin. Oncol. 2008; 26; 983-994.
102. Bussolati G, Leonardo E. Technical pitfalls potentially affecting diagnoses in immunohistochemistry. J. Clin. Pathol. 2008; 61; 1184-1192.
103. Schmid K, Oehl N, Wrba F et al. EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. Clin. Cancer Res. 2009; 15; 4554-4560.
104. Park S, Holmes-Tisch AJ, Cho EY et al. Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumours and lymph node metastasis in non-small cell lung cancer. J. Thorac. Oncol. 2009; 4; 809-815.
105. Taillade L, Penault-Llorca F, Boulet T et al. Immunohistochemichal expression of biomarkers: a comparative study between diagnostic bronchial biopsies and surgical specimens of non-small-cell lung cancer. Ann. Oncol. 2007; 18; 1043-1050.
106. Meert AP, Martin B, Verdebout JM et al. Correlation of different markers (p53, EGF-R, c-erbB2, Ki-67) expression in the diagnostic biopsies and the corresponding resected tumours in non-small cell lung cancer. Lung Cancer 2004; 44; 295-301.
107. Viberti L, Papotti M, Abbona GC et al. Value of Ki-67 immunostaining in pre-operative biopsies of carcinomas of the lung. Hum. Pathol. 1997; 28; 189-192.
108. Bozzetti C, Nizzoli R, Guazzi A et al. Biological parameters on computed tomography guided fine needle aspiration biopsy from peripheral primary non-small cell lung cancer. Lung Cancer 2002; 35; 243-247.
109. Sakurada A, Lara-Guerra H, Liu N et al. Tissue heterogeneity of EGFR mutation in lung adenocarcinoma. J. Thorac. Oncol. 2008; 3; 527-529.
110. Gomez-Roca C, Reynaud CM, Penault-Llorca F et al. Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites. J. Thorac. Oncol. 2009; 4; 1212-1220.
111. Italiano A, Burel Vandenbos F, Otto J et al. Comparison of the epidermal growth factor receptor gene and protein in primary non-small cell lung cancer and metastatic sites: implications for treatment with EGFR inhibitors. Ann. Oncol. 2006; 17; 981-985.
112. Kalikaki A, Koutsopoulos A, Trypaki M et al. Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. Br. J. Cancer 2008; 99; 923-929.